Rob Stein

Moderna saysa new version of its COVID-19 vaccine appears to provide strong protection against the omicron variant as well as the original viral strain.

The "bivalent" vaccine — meaning it targets two different antigens — is Moderna's leading candidate for an effective booster this fall. If the data pan out, it could lead to a yearly booster.

The Food and Drug Administration advisory committee recommends the agency authorize another COVID-19 vaccine in the hopes it might entice more people to get vaccinated.

Advisers to the Food and Drug Administration overwhelmingly voted to recommend that it authorize Novavax's two-dose vaccine against COVID-19.

FDA scientists say another COVID-19 vaccine appears to be highly effective, potentially offering a new tool to entice the millions of people who still aren't vaccinated to finally get inoculated.

FDA scientists have concluded that a new COVID vaccine — that could appeal to some vaccine-hesitant people — appears to be safe and effective, which means it may soon win authorization.

The Novavax vaccine appears to be about 90% effective at preventing mild, moderate and severe COVID-19, Food and Drug Administration scientists say in an analysis of the company's data.

The White House says babies, toddlers and other very young children could finally start getting vaccinated against COVID-19 as soon as June 21.

COVID-19 vaccinations for children younger than 5 could start right after the Juneteenth holiday.

The first results from an in-depth investigation of long COVID produced provocative results. Researchers don't understand the mechanism behind the lingering symptoms but found a link with anxiety.

A detailed study of long-COVID patients fails to find any obvious physical explanation for their lingering health problems. The findings underscore the need for doctors to go beyond routine tests.

Pfizer and BioNTech say three shots of their low-dose pediatric COVID vaccine appears to safely stimulate the immune systems of babies, toddlers and young children to protect them against omicron.

Three shots of the Pfizer-BioNTech COVID-19 vaccines for kids 6 months to under 5 prompted a strong immune response. Preliminary data suggests the vaccine is effective and safe.

An even more contagious omicron subvariant is fueling yet another surge of infections in the U.S. The number of hospitalizations is growing.

The virus became the third leading cause of death in the U.S., and caused so many to die in the prime of life that the country experienced the biggest drop in life expectancy since World War II.

The Food and Drug Administration expanded authorization of Pfizer-BioNTech's COVID vaccine to enable kids ages 5 to 11 who were vaccinated at least five months ago to get a third shot.

As the U.S. approaches 1 million COVID-19 deaths, cases and hospitalizations have started rising again, deaths are poised to creep up again, and the nation is on alert for yet another surge.

President Biden marks the approaching 1 million death toll from COVID in the U.S. More people have died from COVID-19 than died from AIDS in the US since that pandemic began decades ago.

President Biden is honoring the loss of at least 1 million deaths from COVID-19 Thursday morning. The ceremony comes as part of an international summit on the pandemic that the White House is hosting.

The company says a low-dose version of its vaccine triggers an immune response in children ages 6 months to less than 6 years equivalent to what has protected older children and adults.